Cervical cancer is one of the three gynecological malignancies. Its high incidence，recurrence rate and transfer rate make it as a focus of lots of research. Previous research has clearly confirmed that infection of persistent human papilloma virus（HPV），especially the high-risk HPV infection，is the major cause of cervical cancer. The most commonly used treatments include surgery，radiotherapy，chemotherapy，immunotherapy，etc. The HPV gene vaccine，particularly in the target of E7 gene，can induce an specific immune response to control tumor growth，and it has been a research hot spot on the treatment of cervical cancer. But there is a common problem of reduced immunogenicity of gene vaccine when it is applied to the human body. Interleukin-15（IL-15）gene as a vaccine adjuvant used to promote antigen-specific immune responses can significantly improve immunogenicity. The prospect of IL-15 combined with HPV gene vaccine in the treatment of cervical cancer is reviewed，and the feasibility of its application and the value of immunotherapy in treatment of cervical cancer are discussed after consulting literature.